Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 1,089,844 shares were traded during mid-day trading, an increase of 9% from the previous session's volume of 1,003,813 shares.The stock last traded at $20.53 and had previously closed at $21.65.
Wall Street Analyst Weigh In
CAPR has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Maxim Group upped their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a report on Friday, September 20th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.60.
View Our Latest Stock Analysis on CAPR
Capricor Therapeutics Price Performance
The stock has a market cap of $578.50 million, a PE ratio of -22.52 and a beta of 4.01. The stock's fifty day moving average is $6.05 and its 200-day moving average is $5.67.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. On average, sell-side analysts expect that Capricor Therapeutics Inc will post -1.14 EPS for the current fiscal year.
Insider Buying and Selling at Capricor Therapeutics
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.00% of the company's stock.
Institutional Trading of Capricor Therapeutics
Several institutional investors have recently added to or reduced their stakes in CAPR. Vanguard Group Inc. grew its stake in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after buying an additional 200,499 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $426,000. Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after buying an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Institutional investors and hedge funds own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
